Medicis Pharmaceuticals Corporation (MRX)
MRX (:Drugs)
$43.98
+0.02
+0.05%
Today's Range: 43.98 - 44.00 |
MRX Avg Daily Volume: 1,775,200
| Last Update: 12/10/12 - 4:00 PM EST |
| Volume: 1,776,048 |
| YTD Performance: 0.00%
|
| Open: $43.99 |
| Previous Close: $43.96 |
| 52 Week Range: $30.30 -
$44.00 |
| Oustanding Shares: 58,393,411 |
| Market Cap: 2,568,142,216 |
6-Month Chart
TheStreet Ratings Grade for MRX
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
2 |
2 |
2 |
4 |
| Moderate Buy |
0 |
0 |
0 |
0 |
| Hold |
11 |
11 |
11 |
10 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.69 |
2.69 |
2.69 |
2.43 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
0.00 |
|
| Price Earnings Comparisons: |
| MRX |
Sector Avg. |
S&P 500 |
| 0.00 |
34.40 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
0.00%
|
0.00%
|
0.00%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
3.00 |
0.39 |
0.12 |
| Net Income |
2.60 |
9.41 |
1.17 |
| EPS |
1.10 |
10.33 |
1.23 |
| Earnings for MRX: |
| EBITDA |
0.24B |
| Revenue |
0.72B |
|
Average Earnings Estimates
;Qtr (12/12);FY (12/12);FY (12/13)&HEADING_LIST1=Qtr (09/11);Qtr (12/11);FY (12/11);FY (12/12)) |
|
| Average Estimate |
$0.49 |
$0.72 |
$2.35 |
$2.69 |
| Number of Analysts |
10 |
15 |
13 |
16 |
| High Estimate |
$0.55 |
$0.80 |
$2.46 |
$3.31 |
| Low Estimate |
$0.42 |
$0.60 |
$2.13 |
$2.16 |
| Prior Year |
$0.56 |
$0.56 |
$2.40 |
$2.35 |
| Growth Rate (Year over Year) |
-12.14% |
29.40% |
-2.21% |
14.46% |
| Nov 23, 2012 | 2:16 PM EST
Face it, when you live and breathe stocks, there are no holidays, you have-to look.
| Sep 04, 2012 | 10:48 AM EDT
Motivated CEOs, innovative products and smart deals count more than macro events.
Aug 13, 2012 | 7:42 AM EDT
Shares of MRX now seen reaching $33, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Underperform...
May 14, 2012 | 8:11 AM EDT
Shares of MRX now seen reaching $49, Jefferies said. Estimates also raised on biggest upside report in recent memory. Buy rating.
Mar 09, 2012 | 7:27 AM EST
MRX was upgraded to Buy, Goldman Sachs said. $43 price target. Company is focused on generating new growth.
Mar 05, 2012 | 8:19 AM EST
MRX estimates raised through 2013, Jefferies said. Zyclara launch is first in three years. Buy rating.
Jan 27, 2012 | 8:00 AM EST
MRX was initiated with a Hold rating, Cantor Fitzgerald said. $34 price target. Company appears to have reached a growth plateau.
Jan 09, 2012 | 7:27 AM EST
MRX was downgraded from Buy to Hold, Canaccord Genuity said. $36 price target. Company lacks near-term catalysts.
| Dec 28, 2011 | 8:30 AM EST
That trend will likely continue all week.
Dec 28, 2011 | 7:55 AM EST
MRX estimates lowered through 2015, Goldman Sachs said. Reflects updated company guidance. Maintain $38 price target and Ne...
